Zum Inhalt springen
LURIC

Publikation · PMID 34568379

Combined Use of Serum Uromodulin and eGFR to Estimate Mortality Risk

Yazdani B, Delgado GE, Scharnagl H, Krämer BK, Drexel H, März W, Scherberich JE, Leiherer A et al.

Serum uromodulin (sUmod) and eGFR were combined to assess all-cause mortality risk in 3,057 LURIC and 529 VIVIT participants categorized into four groups by median marker values. Compared with patients high on both markers, hazard ratios in LURIC were 2.03, 1.43, and 1.32 for both-low, eGFR-only-low, and sUmod-only-low groups, respectively. Adding sUmod to eGFR-based models improved the AUC, indicating that joint assessment enables more precise mortality risk stratification.

Frontiers in Medicine, 8. September 2021 | PMID 34568379

Zeitschrift
Frontiers in Medicine
DOI
10.3389/fmed.2021.723546
PMID
34568379
Quelle
https://pubmed.ncbi.nlm.nih.gov/34568379/
Zitationen
8 Relative Zitationsrate 0.62 (1,0 = Durchschnitt des Fachgebiets) · NIH iCite, Stand 16.08.2026